Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers

Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers

Breast cancer development in BRCA1/2 mutation carriers is a net consequence of cell-autonomous and cell nonautonomous factors which may serve as excellent targets for cancer prevention. In light of our previous data we sought to investigate the consequences of the BRCA-mutation carrier state on RANK...

Full description

Bibliographic Details
Main Authors: Martin Widschwendter, Matthew Burnell, Lindsay Fraser, Adam N. Rosenthal, Sue Philpott, Daniel Reisel, Louis Dubeau, Mark Cline, Yang Pan, Ping-Cheng Yi, D. Gareth Evans, Ian J. Jacobs, Usha Menon, Charles E. Wood, William C. Dougall
Format: Article
Language:English
Published: Elsevier 2015-10-01
Series:EBioMedicine
Subjects:
Breast cancer
BRCA1 and BRCA2 mutations
RANKL
OPG
Carcinogenesis
Cancer prevention
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396415301195

Internet

http://www.sciencedirect.com/science/article/pii/S2352396415301195

Similar Items